Clinical trial
The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36…
NCT00404768 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00404768 |
|---|---|
| Title | The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor |
| Official title | A Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK221149A Administered Intravenously and to Investigate the Pharmacokinetics of GSK221149A Administered Orally to Healthy, Pregnant Females With… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Obstetric Labour, Premature |
| Intervention type | Drug |
| Interventions | GSK221149A, Placebo |
| Enrollment | 93 |
| Start date | Oct 12, 2007 |
| Primary completion | Jul 7, 2011 |
| Completion | Jul 7, 2011 |
| First posted | Nov 29, 2006 |
| Last update posted | Jan 16, 2018 |
| Countries | Argentina, Bulgaria, Colombia, France, Lithuania, Puerto Rico, Singapore, South Korea, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: